Trials / Completed
CompletedNCT00099216
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 708 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivastigmine |
Timeline
- Start date
- 2001-08-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2004-12-10
- Last updated
- 2011-11-17
Locations
63 sites across 10 countries: United States, Austria, Canada, France, Germany, Italy, Russia, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00099216. Inclusion in this directory is not an endorsement.